NCT03365661 is a Phase 2 clinical trial of ALT-803 in High-Risk Acute Myeloid Leukemia, sponsored by Masonic Cancer Center, University of Minnesota.

Who is sponsoring NCT03365661?

NCT03365661 is sponsored by Masonic Cancer Center, University of Minnesota.

What drugs are being tested in NCT03365661?

Interventions in NCT03365661: ALT-803.

What condition does NCT03365661 study?

NCT03365661 studies High-Risk Acute Myeloid Leukemia, Treatment-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Myelodysplastic Syndrome.

Is NCT03365661 still recruiting?

NCT03365661 is currently withdrawn. Last updated 9 November 2018.

Last reviewed 2018-11-09 · How we verify

NCT03365661

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Withdrawn Phase 2 Last updated 9 November 2018

What this trial tests

Phase 2 trial testing ALT-803 in High-Risk Acute Myeloid Leukemia. Withdrawn.

Timeline

30 October 2018

Primary endpoint
1 January 2023

1 January 2023

Quick facts

Lead sponsor	Masonic Cancer Center, University of Minnesota
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	30 October 2018
Primary completion	1 January 2023
Estimated completion	1 January 2023
Sites	1 location across United States

Drugs / interventions tested

ALT-803 — full drug profile →

Conditions studied

High-Risk Acute Myeloid Leukemia — all drugs for High-Risk Acute Myeloid Leukemia →
Treatment-Related Acute Myeloid Leukemia — all drugs for Treatment-Related Acute Myeloid Leukemia →
Secondary Acute Myeloid Leukemia — all drugs for Secondary Acute Myeloid Leukemia →
Myelodysplastic Syndrome — all drugs for Myelodysplastic Syndrome →

Sponsor

Masonic Cancer Center, University of Minnesota

Who can join

Adults 18 to 70, any sex, with High-Risk Acute Myeloid Leukemia or Treatment-Related Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II multi-institutional therapeutic study of a non-myeloablative T cell receptor (TCR) alpha/beta depleted haploidentical transplantation with post-transplant immune reconstitution using ALT-803 for the treatment of high-risk myeloid leukemia (AML), treatment-related/secondary AML, and myelodysplastic syndrome (MDS).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation.
Yu M, Yang W, Yue W, Chen Y. · · 2022 · cited 35× · PMID 36257824 · DOI 10.1002/advs.202204335
Advancements in nanomedicines for cancer therapy: targeting molecular signaling pathways, activating immune cells, and using photothermal immunomodulation.
Deb VK, Mukherjee A, Pathak S, Paul S, et al · · 2026 · PMID 42040777 · DOI 10.3389/fbioe.2026.1775442

Verify or expand the search:

Other trials of ALT-803

Trials testing the same drug.

NCT03003728 — 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) · Phase 2 · withdrawn
NCT03563157 — QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine · Phase 1, PHASE2 · terminated
NCT03647423 — QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. · Phase 1, PHASE2 · withdrawn
NCT03586869 — QUILT-3.080: NANT Pancreatic Cancer Vaccine · Phase 1, PHASE2 · terminated
NCT03387098 — QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care · Phase 1, PHASE2 · terminated

Other recruiting trials for High-Risk Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07183878 — Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY · NA · recruiting
NCT07237230 — Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transpla · NA · recruiting

Other Masonic Cancer Center, University of Minnesota trials

Trials by the same sponsor.

NCT06772090 — Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies · NA · not yet recruiting
NCT06584929 — Rural Smoking Cessation · NA · not yet recruiting
NCT07153016 — LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorect · NA · recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT07070726 — UNTOLD Ovarian Cancer Unmet Needs Survey · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03365661 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota
Last refreshed: 9 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03365661.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing